Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2016

01-08-2016 | Short Research Report

Identification of patients with atrial fibrillation in UK community pharmacy: an evaluation of a new service

Authors: M. J. Twigg, T. Thornley, N. Scobie

Published in: International Journal of Clinical Pharmacy | Issue 4/2016

Login to get access

Abstract

Background Many patients with atrial fibrillation (AF) are asymptomatic and diagnosed via opportunistic screening. Community pharmacy has been advocated as a potential resource for opportunistic screening and lifestyle interventions. Objective The objective of this evaluation is to describe the outcomes from an AF service, in terms of referrals and interventions provided to patients identified as not at risk. Methods Eligibility was assessed from pharmacy records and the completion of a short questionnaire. Once consented, patients were screened for AF and their blood pressure was measured. Results Of 594 patients screened, nine were identified as at risk of having AF and were referred to their GP. The service also identified 109 patients with undiagnosed hypertension, 176 patients with a Body Mass Index >30, 131 with an Audit-C score >5 and 59 smokers. Pharmacists provided 413 interventions in 326 patients aimed at weight reduction (239), alcohol consumption (123) and smoking cessation (51). Conclusion This evaluation characterises the interventions provided to, not only those identified with the target condition—in this case AF—but also those without it. The true outcome of these additional interventions, along with appropriate follow-up, should be the focus of future studies.
Literature
2.
go back to reference Brüggenjürgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Müller-Nordhorn J, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health. 2007;10(2):137–43.CrossRefPubMed Brüggenjürgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Müller-Nordhorn J, et al. The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. Value Health. 2007;10(2):137–43.CrossRefPubMed
3.
go back to reference Le Page P, MacLachlan H, Anderson L, Penn L-A, Moss A, Mitchell AR. The efficacy of a smartphone ECG application for cardiac screening in an unselected island population. Br J Cardiol. 2015;22:31–3.CrossRef Le Page P, MacLachlan H, Anderson L, Penn L-A, Moss A, Mitchell AR. The efficacy of a smartphone ECG application for cardiac screening in an unselected island population. Br J Cardiol. 2015;22:31–3.CrossRef
4.
go back to reference Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111(6):1167–76.CrossRefPubMed Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost. 2014;111(6):1167–76.CrossRefPubMed
5.
go back to reference Department of Health. Pharmacy in England: building on strengths—delivering the future. London: The Stationery Office; 2008. ISBN 978-0-10-173412-7. Department of Health. Pharmacy in England: building on strengths—delivering the future. London: The Stationery Office; 2008. ISBN 978-0-10-173412-7.
6.
go back to reference Twigg MJ, Wright DJ, Thornley T, Haynes L. Community pharmacy type 2 diabetes risk assessment: demographics and risk results. Int J Pharm Pract. 2015;23(1):80–2.CrossRefPubMed Twigg MJ, Wright DJ, Thornley T, Haynes L. Community pharmacy type 2 diabetes risk assessment: demographics and risk results. Int J Pharm Pract. 2015;23(1):80–2.CrossRefPubMed
7.
go back to reference Willis A, Rivers P, Gray LJ, Davies M, Khunti K. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting. PLoS ONE. 2014;9(4):e91157.CrossRefPubMedPubMedCentral Willis A, Rivers P, Gray LJ, Davies M, Khunti K. The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting. PLoS ONE. 2014;9(4):e91157.CrossRefPubMedPubMedCentral
8.
go back to reference Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA, for the Ambulatory Care Quality Improvement P. The audit alcohol consumption questions (audit-c): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789–95.CrossRefPubMed Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA, for the Ambulatory Care Quality Improvement P. The audit alcohol consumption questions (audit-c): an effective brief screening test for problem drinking. Arch Intern Med. 1998;158(16):1789–95.CrossRefPubMed
9.
go back to reference Hobbs R, Fitzmaurice D, Jowett S, Mant J, Murray E. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: the SAFE study. Health Technol Assess. 2005;9(40):90.CrossRef Hobbs R, Fitzmaurice D, Jowett S, Mant J, Murray E. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: the SAFE study. Health Technol Assess. 2005;9(40):90.CrossRef
10.
go back to reference Eades CE, Ferguson JS, O’Carroll RE. Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health. 2011;11:582.CrossRefPubMedPubMedCentral Eades CE, Ferguson JS, O’Carroll RE. Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health. 2011;11:582.CrossRefPubMedPubMedCentral
Metadata
Title
Identification of patients with atrial fibrillation in UK community pharmacy: an evaluation of a new service
Authors
M. J. Twigg
T. Thornley
N. Scobie
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0303-8

Other articles of this Issue 4/2016

International Journal of Clinical Pharmacy 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.